AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01594359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified beans
Description: Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
Study NCT01594359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BEAN
Description: Placebo
Study NCT03509571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
Study NCT03509571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Diet
Description: Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
Study NCT00108082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol MR
Description: Study drug
Study NCT00108082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: Comparator
Study NCT00108082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Comparator
Study NCT03340987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular incision subperiosteal tunnel access
Description: vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
Study NCT03340987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap
Description: Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
Study NCT02558465 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment parameters following the summary of product characteristics and the physician's decision
Study NCT02792218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab subcutaneous injection
Description: Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study NCT02792218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide-matching placebo capsules
Description: Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
Study NCT02792218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide capsule
Description: Teriflunomide 14 mg oral capsule taken once daily
Study NCT02792218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo of ofatumumab subcutaneous injections
Description: Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study NCT04509999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 Mg Oral Tablet
Description: Bicalutamide 150 mg by mouth daily
Study NCT04509999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as formulated by mouth daily
Study NCT02380313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
Study NCT02380313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
Study NCT02380313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
Study NCT02273232 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care
Description: Standard Care for peripheral vascular disease patients including advises regarding exercises
Study NCT01461460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 1200 mg
Description: 6 tablet of T-701 FA
Study NCT01461460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: 1 tablet 400 mg Moxifloxacin
Study NCT02273232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care for peripheral vascular disease patients including advises regarding exercises
Study NCT00128193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: Licensed TB reagent, 100 microliters, 5 TU dose.
Study NCT01461460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA 200 mg plus Placebo
Description: 1 tablet of TR-701 FA with 5 tablet placebo
Study NCT01461460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo tablets
Study NCT03781479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Study NCT03781479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT03349697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phyllantus amarus
Study NCT03349697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02800343 — intervention group
Intervention type: PROCEDURE
Intervention: routine administration of 0.9% sodium chloride
Description: 0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
Study NCT02389517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02389517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02389517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT02389517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT04325178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.
Description: Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
Study NCT02385682 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT02169479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone
Study NCT02169479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo
Study NCT00128193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (NaCl) serves as a diluent control in Stage A and B only.
Study NCT01981850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7490677
Description: IV infusion
Study NCT01981850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: IV infusion
Study NCT00597519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Cyclophosphamide
Description: Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery.
Study NCT00597519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation
Description: The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
Study NCT02380313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
Study NCT00410124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
Study NCT00410124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01649635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: solution Route of administration: intravenous
Study NCT01649635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT01649635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT01649635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Granulocyte colony-stimulating factor)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT00578656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: Extensively heated milk
Study NCT02955524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%
Description: One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
Study NCT02955524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride ophthalmic gel 3.5%
Description: 1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
Study NCT02215278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 x 55 g/ bean per arm
Study NCT01767259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination
Study NCT01767259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: Valsartan alone
Study NCT01767259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide alone
Study NCT01026233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg IV every 21 days
Study NCT01847651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vastus Muscle Biopsy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vastus Muscle Biopsy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOLA or placebo
Description: Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
Study NCT01847651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOLA or placebo
Description: Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive assessment (PHES)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive assessment (PHES)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessement (Cogstate)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT02169479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Immediate-release levodopa/carbidopa 100/25 mg
Study NCT01682642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
Study NCT02614963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Butyricum
Description: Irritable bowel syndrome patients treated with Clostridium Butyricum
Study NCT02614963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Irritable bowel syndrome patients treated with placebo
Study NCT00346164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00346164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation
Study NCT00346164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study NCT00346164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy
Study NCT00346164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT02593487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg/d group
Description: rosuvastatin 10mg tablet,q.d. for 12 weeks.
Study NCT02593487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg/d group
Description: rosuvastatin 20mg tablet,q.d. for 12 weeks.
Study NCT04471038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-176
Description: Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
Study NCT04471038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
Study NCT02414373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2mg/ml
Description: local anesthetics, which will epidurally administered
Study NCT02414373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetics, which will epidurally administered
Study NCT02414373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)
Study NCT02414373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)
Study NCT02414373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)
Study NCT02414373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)
Study NCT01402154 — intervention group
Intervention type: BIOLOGICAL
Intervention: EPISPOT detection of the number of circulating cells
Description: EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
Study NCT01402154 — intervention group
Intervention type: BIOLOGICAL
Intervention: CellSearch detection of the number of circulating, functional, prostate cells
Description: CellSearch detection of the number of circulating, functional, prostate cells per unit blood
Study NCT02345291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRD135S.E1
Description: A small chemical entity for treatment of neuropathic pain NRD135S.E1
Study NCT02345291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match NRD135S.E1
Description: Placebo capsule to match NRD135S.E1 capsules
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Assessement (Cogstate)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood and urine sampling
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blood and urine sampling
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional assessment
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional assessment
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI brain and spectroscopy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI brain and spectroscopy
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI leg cross section
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI leg cross section
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (working memory and attention tasks)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT01847651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional MRI (working memory and attention tasks)
Description: Both Arms, all 3 visits at 0, 4 and 12 weeks
Study NCT04174495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DXA and CT-scan
Description: DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
Study NCT04361279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-02
Description: Injection，100mg/10ml
Study NCT01566513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Connector
Description: The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
Study NCT01566513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Mentor
Description: A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
Study NCT01566513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Case Manager
Description: A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.